The objectives of this dose escalation study are to confirm the optimal dose of transplanted hepatocytes to safely achieve adequate allogeneic hepatocyte (AH) engraftment into the periduodenal lymph nodes (PDLNs) via endoscopic ultrasound (EUS) in subjects with end-stage liver disease.
Allogenic Hepatocyte Transplantation into Periduodenal Lymph Nodes
A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease
Liver diseases
All genders
18-70
Recruiting now
Overview
Principal Investigator: Raffi Karagozian, MD
Contact Us
Obi Abalihi
Study details
Inclusion Criteria
- Subjects must have a diagnosis of end-stage liver disease (ESLD) due to alcohol, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, autoimmune hepatitis, primary sclerosis cholangitis, primary biliary cirrhosis (cholangitis), cirrhosis as the result of Wilson disease, hemochromatosis, sarcoidosis and alpha 1 antitrypsin deficiency, cryptogenic cirrhosis and nonalcoholic steatohepatitis cirrhosis with a MELD-Na score >10 to <25 at screening.
- Subjects have a Body Mass Index (BMI) <35.
- Subject must have stable control of portal hypertension and upper gastrointestinal bleeding with medical therapy and/or endoscopic therapy.
Exclusion Criteria
- Subject has primary hepatic neoplasms (hepatocellular carcinoma and cholangiocarcinoma).
- Subject has active and/or uncontrolled severe infections requiring hospitalization and prolonged antimicrobial therapy.
- Subject has an extrahepatic neoplastic disease requiring active chemotherapy, immunotherapy, and/or surgical resection.
Study Requirements
The total duration of the study is expected to be approximately 24 months, including 3 months (12 weeks) for subject recruitment, 9 months for analyses from the dose escalation, and 12 months for safety follow-up visits.
Screening: Up to 3 months (12 weeks).
Treatment: Subjects will receive the hepatocyte transplantation (HT) through the endoscopic ultrasound (EUS) approach. Immediately following the EUS procedure, subjects will be hospitalized overnight for a 23-hour observation period to allow for continuous acute clinical and laboratorial monitoring as needed. The initial follow-up should be weekly for the first month.
Primary Evaluation: 12 weeks after dosing.
Safety/Tolerability/Efficacy Follow-up: conducted throughout the study as Weeks 1, 2, 3, 4, 6, 8, 1